Related Experiment Video
Updated: Mar 16, 2026
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview
Adetola A Kassim1, Alexis A Thompson2, Punam Malik3
1Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Insights
Developing curative treatments for sickle cell disease (SCD) in Africa requires infrastructure, training, and funding. Accessible therapies like hydroxyurea are crucial while building capacity for advanced treatments like gene therapy.
Area of Science:
- Hematology
- Public Health
- Genetics
Background:
- Sickle cell disease (SCD) presents significant challenges in Africa, necessitating the development of accessible curative treatments.
- Existing healthcare infrastructure and resources in low- and middle-income countries pose barriers to advanced therapies.
Purpose of the Study:
- To outline the practical considerations for implementing curative SCD treatments in Africa.
- To identify strategies for overcoming economic, ethical, and logistical hurdles in SCD management.
Main Methods:
- The study reviews essential components for developing curative SCD therapies, including infrastructure, workforce training, and national programs.
- It examines cost-effectiveness strategies, ethical guidelines, and the importance of early diagnosis and public awareness.
- The role of accessible disease-modifying therapies as a precursor to curative treatments is emphasized.
Main Results:
- Successful implementation of gene therapy and stem cell transplantation requires substantial healthcare system strengthening.
- Affordability and equitable access are critical, necessitating local manufacturing, government support, and global partnerships.
- Integrating newborn screening and continuous clinical care is vital for identifying eligible patients.
Conclusions:
- A pragmatic approach involves prioritizing accessible disease-modifying therapies while concurrently building capacity for advanced curative treatments.
- International collaboration is essential for knowledge sharing and resource optimization in SCD management.
- Addressing cultural factors and promoting positive attitudes are key to successful SCD care and treatment adoption.
Abstract:
The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professionals, establishing regional treatment centers, and creating national SCD programs. The costs associated with gene therapy and stem cell transplants can be prohibitive, especially in low- and middle-income countries. Strategies to address affordability, including local manufacturing, government funding, and partnerships with global health agencies, are essential to ensure equitable access. Establishing ethical and regulatory guidelines while raising awareness among patients and communities is critical. Early diagnosis through newborn screening and adequate clinical care programs are vital for identifying individuals with SCD who could benefit from curative therapies and other interventions. Addressing cultural beliefs and promoting positive attitudes toward SCD and its management is essential. While curative therapies offer hope, hydroxyurea and other disease-modifying therapies with established clinical benefits are more accessible in many settings. Prioritizing these medications ensures that patients with SCD are medically prepared to receive curative therapies while simultaneously building capacity for advanced treatments, thus creating a pragmatic approach. Lastly, international collaboration and partnerships among researchers, global health agencies, and local organizations are vital for sharing knowledge, resources, and best practices in SCD management.
More Related Videos
Related Concept Videos
01:22iPS Cell Differentiation
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
00:59Gene Therapy